{"id":"rivaroxaban-10mg","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":"1-2","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1","effect":"Intracranial hemorrhage"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban selectively inhibits Factor Xa, a serine protease essential for both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby reducing thrombin-mediated fibrin clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:24.827Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) treatment and prevention"},{"name":"Pulmonary embolism (PE) treatment and prevention"},{"name":"Acute coronary syndrome (ACS) in combination with antiplatelet therapy"}]},"trialDetails":[{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT06965998","phase":"PHASE2, PHASE3","title":"A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-08-06","conditions":"SVT, Thrombosis, Superficial Vein Thrombosis","enrollment":50},{"nctId":"NCT06580223","phase":"PHASE3","title":"Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-01","conditions":"Multiple Myeloma, Venous Thromboembolism","enrollment":530},{"nctId":"NCT06831474","phase":"PHASE1","title":"Excretion of Rivaroxaban in Human Breast Milk","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-07","conditions":"Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism)","enrollment":10},{"nctId":"NCT05029063","phase":"PHASE3","title":"Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-10-05","conditions":"Venous Thromboembolism, Cancer","enrollment":1828},{"nctId":"NCT06689241","phase":"NA","title":"Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-10-01","conditions":"Morbid Obesity, Bariatric Surgery Candidate","enrollment":162},{"nctId":"NCT05033314","phase":"PHASE3","title":"THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2022-06-07","conditions":"Sickle Cell Disease, Central Venous Catheter Thrombosis, Venous Thromboembolism","enrollment":4},{"nctId":"NCT05775965","phase":"PHASE2","title":"HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-05-21","conditions":"Hip Fractures","enrollment":250},{"nctId":"NCT03522259","phase":"PHASE2","title":"Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-07-19","conditions":"Bariatric Surgery","enrollment":272},{"nctId":"NCT06108414","phase":"PHASE4","title":"Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-09-01","conditions":"Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke","enrollment":4374},{"nctId":"NCT03506815","phase":"PHASE3","title":"Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2019-03-15","conditions":"Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer","enrollment":105},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT03428373","phase":"PHASE2, PHASE3","title":"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-01-17","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II","enrollment":57},{"nctId":"NCT04075240","phase":"PHASE3","title":"VTE Prevention Following Total Hip and Knee Arthroplasty","status":"RECRUITING","sponsor":"Sudeep Shivakumar","startDate":"2021-02-04","conditions":"Venous Thromboembolism","enrollment":5400},{"nctId":"NCT03864406","phase":"PHASE1","title":"Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2019-06-04","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT05143567","phase":"NA","title":"Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2021-11-01","conditions":"Venous Thromboembolism, covid19, Thrombosis","enrollment":150},{"nctId":"NCT02829957","phase":"PHASE2, PHASE3","title":"RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-09","conditions":"Venous Thromboembolism, Menstruation","enrollment":19},{"nctId":"NCT05449327","phase":"NA","title":"Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Chiayi Christian Hospital","startDate":"2023-02-01","conditions":"Venous Thromboembolism, Arthroplasty","enrollment":178},{"nctId":"NCT05960721","phase":"NA","title":"Low-dose NOAC Versus GDMT After LAAO","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-07-06","conditions":"Atrial Fibrillation","enrollment":4220},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT03331484","phase":"PHASE3","title":"The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-11-01","conditions":"Atrial Fibrillation, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT05658042","phase":"","title":"Dose Optimization of Rivaroxaban Combined With Rifampicin","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-07-01","conditions":"Infections","enrollment":80},{"nctId":"NCT03746301","phase":"","title":"Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-03","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":924},{"nctId":"NCT05638100","phase":"","title":"Efficacy and Safety of Different Doses of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-01-01","conditions":"Atrial Fibrillation","enrollment":300},{"nctId":"NCT03005444","phase":"NA","title":"Anticoagulation for Advanced Cirrhotic Patients After TIPS","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2017-06-14","conditions":"Liver Cirrhosis","enrollment":254},{"nctId":"NCT04662684","phase":"PHASE3","title":"Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial","status":"COMPLETED","sponsor":"Science Valley Research Institute","startDate":"2020-10-16","conditions":"Covid19, Venous Thromboembolism","enrollment":320},{"nctId":"NCT05303818","phase":"PHASE4","title":"Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer","status":"UNKNOWN","sponsor":"Hospital do Servidor Publico Estadual","startDate":"2022-06-01","conditions":"Deep Venous Thrombosis, Colonic Cancer","enrollment":68},{"nctId":"NCT03273322","phase":"PHASE2, PHASE3","title":"Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-13","conditions":"Atrial Fibrillation, Atrial Appendage, Hemorrhage","enrollment":105},{"nctId":"NCT04397289","phase":"PHASE1, PHASE2","title":"Anticoagulation Therapy After Splenectomy in Cirrhosis Patient","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-02-12","conditions":"Liver Cirrhosis, Portal Hypertension, Anticoagulant-induced Bleeding","enrollment":70},{"nctId":"NCT03328832","phase":"PHASE4","title":"Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-09-12","conditions":"Osteoarthritis, Knee","enrollment":70},{"nctId":"NCT04640181","phase":"PHASE2","title":"Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)","status":"COMPLETED","sponsor":"St. David's HealthCare","startDate":"2020-12-01","conditions":"Covid19","enrollment":150},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04753489","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2021-02-13","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04256525","phase":"PHASE4","title":"Prophylactic Anticoagulation for Catheter-related Thrombosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Venous Thrombosis Due to Central Venous Access Device (Disorder), Prophylactic Anticoagulation, Patients With Tumor","enrollment":1640},{"nctId":"NCT04309240","phase":"PHASE3","title":"Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports","status":"UNKNOWN","sponsor":"LiuZhou People's Hospital","startDate":"2020-03-08","conditions":"Rivaroxaban, Thromboprophylaxis, Cancer","enrollment":204},{"nctId":"NCT02833948","phase":"PHASE3","title":"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2016-05","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases","enrollment":231},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT03196349","phase":"PHASE4","title":"Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-08-01","conditions":"Venous Thromboembolism","enrollment":44},{"nctId":"NCT03282643","phase":"PHASE1, PHASE2","title":"Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-02-16","conditions":"Neoplasms","enrollment":74},{"nctId":"NCT02401594","phase":"PHASE3","title":"PROphylaxis in NOn Major Orthopaedic Surgery","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-12-08","conditions":"Non-major Orthopaedic Surgery","enrollment":3608},{"nctId":"NCT02123524","phase":"PHASE3","title":"Rivaroxaban Anticoagulation for Superficial Vein Thrombosis","status":"COMPLETED","sponsor":"McMaster University","startDate":"2014-11-11","conditions":"Symptomatic Superficial Vein Thrombosis","enrollment":85},{"nctId":"NCT01962545","phase":"PHASE4","title":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study","status":"COMPLETED","sponsor":"Satoshi Shizuta","startDate":"2013-11-05","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":690},{"nctId":"NCT02643212","phase":"PHASE3","title":"Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis","status":"UNKNOWN","sponsor":"David Garcia Cinca","startDate":"2016-05","conditions":"Cirrhosis","enrollment":160},{"nctId":"NCT01720108","phase":"PHASE3","title":"Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty","status":"COMPLETED","sponsor":"David Anderson","startDate":"2013-02-24","conditions":"Venous Thromboembolism","enrollment":3426},{"nctId":"NCT03277001","phase":"NA","title":"Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2017-10-01","conditions":"Acute Exacerbation Copd, Venous Thromboembolism","enrollment":438},{"nctId":"NCT01094886","phase":"PHASE3","title":"Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-03","conditions":"Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":56},{"nctId":"NCT02042534","phase":"PHASE2","title":"Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2014-01","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":195},{"nctId":"NCT01205932","phase":"PHASE3","title":"Dose-confirmatory Bridging Study in Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-09","conditions":"Venous Thromboembolism","enrollment":402},{"nctId":"NCT01206972","phase":"PHASE3","title":"Dose-confirmatory Bridging Study in Total Knee Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-10","conditions":"Venous Thromboembolism","enrollment":302},{"nctId":"NCT02271399","phase":"PHASE2","title":"Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Hanyang University Seoul Hospital","startDate":"2014-10","conditions":"Venous Thromboembolism","enrollment":156},{"nctId":"NCT01523418","phase":"","title":"Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2014-10","conditions":"Prophylaxis, Thromboembolism, Venous, Total Knee Replacement, Total Hip Replacement","enrollment":""},{"nctId":"NCT02054936","phase":"PHASE4","title":"Evaluation of Wound Drainage After Knee or Hip Arthroplasty","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2014-03","conditions":"Complications; Arthroplasty","enrollment":""},{"nctId":"NCT02537405","phase":"PHASE1","title":"Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-02","conditions":"Embolism, Atrial Fibrillation and Venous Thrombosis","enrollment":40},{"nctId":"NCT02331602","phase":"PHASE4","title":"Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran","status":"UNKNOWN","sponsor":"Yokohama City University Medical Center","startDate":"2013-07","conditions":"Atrial Fibrillation","enrollment":200},{"nctId":"NCT02458729","phase":"PHASE4","title":"The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2012-08","conditions":"Osteoarthritis, Knee","enrollment":294},{"nctId":"NCT02453802","phase":"PHASE4","title":"Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-06","conditions":"Osteoarthritis, Knee","enrollment":90},{"nctId":"NCT02379663","phase":"PHASE4","title":"Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-01","conditions":"Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures","enrollment":639},{"nctId":"NCT00973323","phase":"PHASE2","title":"BAY59-7939 Japanese in Atrial Fibrillation (2nd)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-09","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT00973245","phase":"PHASE2","title":"BAY59-7939 in Atrial Fibrillation Once Daily (OD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Atrial Fibrillation","enrollment":102},{"nctId":"NCT00779064","phase":"PHASE2","title":"BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Atrial Fibrillation","enrollment":36},{"nctId":"NCT00839826","phase":"PHASE2","title":"ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Thromboembolism, Prevention","enrollment":641},{"nctId":"NCT00329628","phase":"PHASE3","title":"Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Venous Thromboembolism","enrollment":4541},{"nctId":"NCT01923818","phase":"PHASE2, PHASE3","title":"Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2013-09","conditions":"Ischemic Stroke, TIA","enrollment":3700},{"nctId":"NCT01344954","phase":"PHASE2","title":"Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2011-04","conditions":"Prophylaxis of Venous Thromboembolic Events","enrollment":632},{"nctId":"NCT01210755","phase":"PHASE4","title":"Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2010-11","conditions":"Venous Thromboembolism","enrollment":10}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"GASTRIC HAEMORRHAGE"},{"count":5,"reaction":"DEEP VEIN THROMBOSIS"},{"count":5,"reaction":"HAEMORRHAGE"},{"count":4,"reaction":"HAEMOGLOBIN DECREASED"},{"count":4,"reaction":"PULMONARY EMBOLISM"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"DIVERTICULUM INTESTINAL HAEMORRHAGIC"},{"count":2,"reaction":"MELAENA"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ASTHENIA"}],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xarelto","Rivaroxaban"],"phase":"marketed","status":"active","brandName":"rivaroxaban (10mg)","genericName":"rivaroxaban (10mg)","companyName":"Chang Gung Memorial Hospital","companyId":"chang-gung-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}